| Cell line name | Hep-2 TPFR |
|---|---|
| Accession | CVCL_GZ00 |
| Resource Identification Initiative | To cite this cell line use: Hep-2 TPFR (RRID:CVCL_GZ00) |
| Comments | Problematic cell line: Contaminated. Parent cell line (HEp-2) has been shown to be a HeLa derivative. Population: African American. Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU). Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18). Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002. |
| Disease | Human papillomavirus-related cervical adenocarcinoma (NCIt: C27677) |
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) |
| Hierarchy | Parent: CVCL_1906 (HEp-2) |
| Sex of cell | Female |
| Age at sampling | 30Y6M |
| Category | Cancer cell line |
| Publications | PubMed=25962396; DOI=10.3892/mmr.2015.3768 |
| Cross-references | |
| Encyclopedic resources | Wikidata; Q54882756 |
| Entry history | |
| Entry creation | 26-Sep-2016 |
| Last entry update | 05-Oct-2023 |
| Version number | 10 |